Compounded <a href="https://glp1place.com/tools/compound/glp-1/”>GLP-1 impurities are not just a theoretical concern. A peer-reviewed study published July 30, 2026 found that tested follow-on and compounded semaglutide and liraglutide products had impurity profiles different from their originator products. Researchers reported amino-acid deletions and additions, unidentified impurities, strength differences, higher-molecular-weight material, and stability changes after light exposure. Higher-molecular-weight material refers to larger peptide-related forms, including possible aggregates. The results do not show that every compounded GLP-1 product is unsafe. They do show that identifying the intended peptide, or reporting a single purity percentage, is not enough to establish pharmaceutical quality.
The study addresses a question often missed in discussions of peptide quality: what else is in the vial besides the intended peptide? A product may contain the labeled active ingredient yet still differ from an originator medicine in peptide-related impurities, aggregates, degradation products, concentration, storage stability, or potential immune recognition. These differences matter for injectable peptides, especially when complete manufacturing and analytical documentation is unavailable.
The paper, published in Pharmaceutical Research, compared analytical and immunogenicity-related characteristics of selected semaglutide and liraglutide follow-on or compounded products with their originator counterparts. The authors used liquid chromatography-mass spectrometry, peptide-presentation assays, photostability testing, and fibrillation assays. Researchers affiliated in part with Novo Nordisk participated in the work, a limitation to consider when interpreting the findings. Even so, the methods and reported results provide a technical framework for understanding why peptide quality cannot be reduced to one purity figure.
What the 2026 compounded GLP-1 impurities study examined
The researchers assessed semaglutide and liraglutide, two GLP-1 receptor agonists with complex manufacturing and quality-control requirements. Their molecular behavior depends not only on the correct amino-acid sequence, but also on chemical modifications, formulation, aggregation behavior, storage stability, and the absence of unwanted related substances.
The study compared originator products with multiple samples described as follow-on drug substances, follow-on products, or compounded products. The authors were not simply asking whether semaglutide or liraglutide could be detected. They assessed whether the tested samples showed the same impurity patterns and physical behavior as the corresponding originator products.
That distinction is central. Identity testing answers a narrow question: is the expected molecule present? Purity testing asks how much measured material appears to be the target compound. Neither alone establishes whether a peptide product has the same impurity profile, stability, tendency to aggregate, or immunogenicity potential as an approved originator medicine.
| Quality question | What it can show | What it cannot establish by itself |
|---|---|---|
| Identity | Whether the expected peptide or a related molecular signal is present | Whether the product contains no harmful impurities or has the same biological behavior as the originator |
| Assay or strength | How much active material is present under the method used | Whether the material is structurally identical, stable, sterile, or free from immunogenic contaminants |
| HPLC purity | How much of the measured chromatographic signal corresponds to the principal peak | Whether unknown impurities, aggregates, endotoxin, or sequence variants are absent |
| Mass spectrometry | Molecular mass and evidence of sequence-related variants | Whether every impurity is clinically relevant or whether the product performs identically in humans |
| Stability testing | How a product changes under defined storage or stress conditions | Whether an unrelated batch made under different conditions has the same shelf life |
The main findings on compounded GLP-1 impurities
Different impurity profiles
The investigators reported that follow-on drug substances and follow-on or compounded products had impurity profiles distinct from those of the originator products. Reported differences included amino-acid deletions, amino-acid additions, and unidentified impurities.
Peptide synthesis is not automatically equivalent to pharmaceutical manufacturing. A peptide can be chemically recognizable as semaglutide or liraglutide while also containing related substances generated during synthesis, purification, formulation, filling, or storage. Some related substances may be present at low levels and have limited practical significance. Others may affect potency, stability, aggregation, or immune recognition. The study does not say that every detected impurity causes harm. It shows that impurity profiles require characterization rather than assumption.
This is why a statement such as 99% pure is incomplete without analytical context. Purity depends on the method, reference standard, integration rules, detection limits, and substances the method can distinguish. A chromatographic principal peak alone does not show that the remaining material is harmless or fully characterized.
Differences in strength and high-molecular-weight material
The study also reported differences in strength, impurity sum, and high-molecular-weight material between tested compounded semaglutide and the originator product after light exposure. High-molecular-weight material can matter because peptide molecules may associate, aggregate, or otherwise change during storage. These changes can affect physical stability and may alter how the immune system encounters the product.
These observations do not show that light exposure affects every compounded GLP-1 product in the same way. They demonstrate a narrower point: products with different manufacturing and formulation histories may respond differently to the same stress condition. Storage information for one formulation cannot establish identical behavior for a product made through a different process.
Potential immunogenicity signals
Using a major histocompatibility complex class II-associated peptide proteomics assay, the researchers examined how impurities from the tested products were presented by immune-related cells from healthy donors. They reported potentially immunogenic peptides, with differences in the number and distribution of presented peptides across samples.
Immunogenicity is the capacity of a substance to provoke an immune response. In peptide therapeutics, immune responses may involve anti-drug antibodies or other pathways that can affect exposure, efficacy, tolerability, or safety. A laboratory signal is not the same as a demonstrated clinical adverse event. The study did not establish that the tested products caused immune-mediated injury in patients. Instead, it identified a plausible quality concern that requires additional analytical and clinical investigation.
The cautious interpretation is that the tested products contained differences capable of changing immune presentation in vitro. Those differences support further quality assessment and immunogenicity research, but they do not establish a particular clinical outcome for an individual product or patient.
Why semaglutide and liraglutide quality is technically complicated
Semaglutide and liraglutide are not simple small-molecule compounds that can be evaluated with one identification test. They are peptides with defined sequences, chemical modifications, formulation requirements, and sensitivity to manufacturing and storage conditions. Their quality profile can be influenced by starting material, coupling chemistry, purification, residual reagents, formulation excipients, container-closure systems, temperature, light, agitation, and time.
The active ingredient must be present at the intended strength and remain chemically and physically stable throughout its labeled shelf life. Related substances need to be detected and assessed. For injectable medicines, sterility, endotoxin, particulate matter, container integrity, and aseptic processing are additional concerns. These controls are separate from a simple purity claim.
GLP1Place’s guide to endotoxin testing, mismatched batches, and peptide quality explains why identity, concentration, sterility, endotoxin, and batch consistency are separate quality dimensions. It is a general educational resource, not product-specific testing or a substitute for regulatory review.
What the study does not prove
The study has meaningful limitations. First, it evaluated selected samples rather than every compounded or follow-on GLP-1 product. Results from one batch, formulation, or source cannot automatically be generalized to all products.
Second, the study included authors affiliated with Novo Nordisk, and the conflict-of-interest statement identified employment or shareholding relationships. That does not automatically invalidate the methods or findings, but the results should be interpreted alongside independent research, regulatory testing, and transparent replication.
Third, laboratory immunogenicity assays do not establish clinical outcomes by themselves. A difference in peptide presentation may indicate a mechanistic concern without showing that patients will develop antibodies or experience a particular adverse event.
Fourth, the study does not establish that legally compounded medication is equivalent to unapproved products distributed outside regulated channels. Pharmacy compounding, outsourcing-facility production, follow-on manufacturing, and unapproved direct-to-consumer distribution involve different regulatory frameworks and quality systems. Treating them as one category would obscure important distinctions.
Even with these limitations, the study supports a defensible conclusion: compounded and follow-on GLP-1 products should be evaluated on their own analytical and manufacturing evidence rather than presumed interchangeable with originator medicines.
How this connects with FDA quality concerns
The study arrives amid continuing FDA concern about unapproved GLP-1 products. FDA states that unapproved versions do not undergo the agency’s premarket review for safety, effectiveness, and quality. The agency has also described concerns involving falsely labeled compounded products, dosing errors, semaglutide salt forms, shipping-temperature problems, and products marketed under the names of pharmacies that did not actually compound them. FDA’s GLP-1 safety and quality notice provides the agency’s current overview.
The peer-reviewed study and FDA notice address different evidence streams. FDA communications describe regulatory findings, adverse-event reports, labeling problems, and supply-chain concerns. The paper provides laboratory evidence about impurity profiles, stability, and potential immune presentation. Together, they show why quality questions extend beyond counterfeit packaging.
A product-quality failure can involve an incorrect ingredient, incorrect strength, uncharacterized related substances, degradation during storage, contamination, or inadequate documentation linking a finished product to validated testing. These are distinct failure modes, although they may overlap when quality controls are inadequate.
Industry impact
The findings may influence how compounders, active-ingredient suppliers, analytical laboratories, regulators, and clinical researchers discuss GLP-1 quality. For manufacturers and compounders, the study illustrates why a certificate of analysis is most informative when supported by validated methods, reference standards, supplier qualification, batch traceability, impurity characterization, stability data, and documented quality-unit oversight.
For analytical laboratories, the paper reinforces the value of orthogonal testing: using different methods that answer different questions. Liquid chromatography, mass spectrometry, peptide mapping, aggregation analysis, and functional assays each add part of the picture. No single test fully characterizes an injectable peptide product.
For researchers, the study also supports more complete reporting of sample provenance. Research involving compounded or follow-on products is easier to interpret when it identifies the source category, batch information, storage history, formulation, analytical methods, and whether samples were tested before or after stress exposure. Without that context, comparisons across studies remain difficult.
Regulatory and compliance notes
Compounded medicines are not FDA-approved products, and FDA does not review them before marketing in the same manner as approved drugs. This does not mean every compounded medicine is defective. It means the regulatory pathway, evidence base, and premarket oversight differ from those for an approved originator product.
FDA has separately stated that retatrutide and cagrilintide cannot be used in compounding under federal law because they are not components of FDA-approved drugs and have not been found safe and effective for any condition. That issue is distinct from the semaglutide and liraglutide analytical study, but it illustrates why approved GLP-1 medicines, investigational compounds, and research-use-only materials should not be treated as interchangeable categories.
In regulatory terms, analytical quality, lawful compounding status, labeling, and evidence of safety and effectiveness are related but separate questions. The 2026 study contributes evidence on analytical comparability for selected samples; it does not decide the legal status of compounding or replace product-specific regulatory review.
Research outlook
Additional independent comparative studies could clarify how often impurity and stability differences occur, which manufacturing variables are most important, and which laboratory findings have clinical relevance. The field would benefit from standardized reference materials, transparent analytical protocols, independent replication, and prospective immunogenicity monitoring where scientifically appropriate.
The study does not support a conclusion that every compounded GLP-1 product has the same defects. It does support differentiating between products backed by transparent, validated quality systems and products for which analytical and manufacturing evidence cannot be independently assessed.
Researcher takeaways
- Do not equate identity with quality. Detecting semaglutide or liraglutide does not establish the absence of related substances, aggregates, endotoxin, contamination, or incorrect strength.
- Purity percentages require method details. The method, reference standard, resolved impurities, and detection limits affect what a reported purity figure means.
- Impurity profiles deserve characterization. Amino-acid additions, deletions, sequence variants, and unidentified peaks should not automatically be treated as interchangeable background signals.
- Stability is product-specific. A formulation made through a different process may respond differently to light, temperature, agitation, or time than an originator product.
- In-vitro immunogenicity signals are not clinical diagnoses. They are evidence supporting further investigation, not proof that a particular product caused an adverse event.
- Conflict-of-interest statements matter. Industry-affiliated research can be informative, while independent replication strengthens confidence and clarifies limits of generalization.
FAQ
What did the 2026 study find about compounded GLP-1 impurities?
The study found that tested follow-on and compounded semaglutide and liraglutide products had impurity profiles different from the originator products. Researchers reported amino-acid deletions, additions, unidentified impurities, strength differences, and stability changes that could affect immune recognition and product quality.
Does the study prove that all compounded semaglutide or liraglutide is unsafe?
No. The study examined selected samples and does not establish that every compounded product is unsafe. It does show that compounded and follow-on products should not automatically be assumed to have the same quality, purity, stability, or immunogenicity profile as an originator product.
What is immunogenicity in a GLP-1 medicine?
Immunogenicity is the capacity of a substance to trigger an immune response. For peptide medicines, altered peptide sequences, aggregates, or other impurities may theoretically change how the immune system recognizes the product.
Why can compounded GLP-1 products have different impurity profiles?
Differences can arise from the source of the active pharmaceutical ingredient, synthesis and purification methods, formulation, filling processes, storage conditions, light exposure, and the quality systems used by the manufacturer or compounder.
What should researchers look for when evaluating GLP-1 product quality?
Researchers should distinguish identity from purity and examine validated analytical testing, peptide mapping, mass spectrometry, impurity characterization, strength testing, sterility or endotoxin controls where applicable, stability data, storage conditions, and traceable batch documentation.
Bottom line: The 2026 study does not justify declaring every compounded GLP-1 product unsafe. It does justify rejecting the assumption that all semaglutide or liraglutide products are analytically interchangeable. For peptide medicines, quality means more than finding the expected molecule. It means demonstrating appropriate structure, strength, impurity characterization, stability, manufacturing controls, and consistent performance.